Isolated lymph node relapse of epithelial ovarian carcinoma: Outcomes and prognostic factors

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 41-45

  Blanchard, Pierre ^a   Plantade, Anne ^a   Pagès, Cécile ^a   Afchain, Pauline ^a   Louvet, Christophe ^a   Tournigand, Christophe ^a   de Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chemotherapy; Lymph node relapse; Natural history; Ovarian carcinoma; Spontaneous remission

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; EARLY CANCER; FEMALE; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846018958     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.039     Document Type: Article

References (26)

1. Eisenhauer E.A., Vermorken J.B., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 10 (1997) 963-968
2. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
3. Ozols R.F. Recurrent ovarian cancer: evidence-based treatment. J. Clin. Oncol. 20 (2002) 1161-1163
4. Dauplat J., Hacker N.F., Nieberg R.K., Berek J.S., Rose T.P., and Sagae S. Distant metastases in epithelial ovarian carcinoma. Cancer 60 (1987) 1561-1566
5. Cormio G., Rossi C., Cazzolla A., et al. Distant metastases in ovarian carcinoma. Int. J. Gynecol. Cancer 13 (2003) 125-129
6. Markman M. Follow-up of the asymptomatic patient with ovarian cancer. Gynecol. Oncol. 55 (1994) S134-S137
7. Sabbatini P., and Spriggs D. Salvage therapy for ovarian cancer. Oncology (Willist. Park) 12 (1998) 833-843
8. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
9. Bolis G., Scarfone G., Luchini L., et al. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. Eur. J. Cancer 30A (1994) 1764-1768
10. Gore M.E., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36 (1990) 207-211
11. van der Burg M.E., Hoff A.M., van Lent M., Rodenburg C.J., van Putten W.L., and Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur. J. Cancer 27 (1991) 248-2450
12. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int. J. Gynaecol. Obstet. 83 Suppl. 1 (2003) 135-166
13. Onda T., Yoshikawa H., Yasugi T., et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 83 (1998) 1555-1560
14. Panici P.B., Maggioni A., Hacker N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J. Natl. Cancer Inst. 97 (2005) 560-566
15. Burghardt E., Girardi F., Lahousen M., Tamussino K., and Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol. Oncol. 40 (1991) 103-106
16. Dvoretsky P.M., Richards K.A., Angel C., et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum. Pathol. 19 (1988) 57-63
17. Kehoe S., Luesley D., and Rollason T. Ovarian carcinoma presenting with inguinal metastatic lymphadenopathy 33 months prior to intraabdominal disease. Gynecol. Oncol. 50 (1993) 128-130
18. Scholz H.S., Lax S., Tamussino K.F., and Petru E. Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: a case report. Gynecol. Oncol. 75 (1999) 517-518
19. Orris B.G., Geisler J.P., and Geisler H.E. Ovarian carcinoma metastatic to bilateral axillary lymph nodes. A case report. Eur. J. Gynaecol. Oncol. 20 (1999) 189-190
20. Recine M.A., Deavers M.T., Middleton L.P., Silva E.G., and Malpica A. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am. J. Surg. Pathol. 28 (2004) 1646-1651
21. Tserkezoglou A., Kontou S., Hatjieleftheriou G., et al. Solitary parenchymal splenic recurrence of ovarian adenocarcinoma: a case report and review of the literature. Anticancer Res. 25 (2005) 1471-1476
22. Uzan C., Morice P., Rey A., et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann. Surg. Oncol. 11 (2004) 658-664
23. Morice P., Joulie F., Rey A., et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur. J. Gynaecol. Oncol. 25 (2004) 169-174
24. Hoskins P., Tu D., James K., et al. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups. Gynecol. Oncol. 70 (1998) 224-230
25. Morice P., Joulie F., Camatte S., Pater J., and Koski B. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J. Am. Coll. Surg. 197 (2003) 198-205
26. Homsi J., Kashani-Sabet M., Messina J.L., and Daud A. Cutaneous melanoma: prognostic factors. Cancer Control 12 (2005) 223-229